Genetics research is providing remarkable insights into the human genome and how this knowledge can be translated into healthcare advances. This scientific progress relies on continued public investment in biomedical research. ASHG supports the robust, predictable, sustainable federal funding of research to fuel scientific advances.
Related:
- Written Testimony to Senate Appropriations LHHS Subcommittee (May 2023)
- Written Testimony to Congress for FY 2024 (March 2023)
- Written Testimony to Congress for FY 2023 (May 2022)
- Written Testimony to Congress for FY 2022 (May 2021)
- Written Testimony to Congress for FY 2021 (March 2020)
- Written Testimony to Congress for FY 2020 (April 2019)
- Community support letter – Dr. Monica Bertagnolli’s confirmation for NIH Director (October 2023)
- Ad Hoc Group for Medical Research community letter: Fiscal Year 2024 Recommendation (March 2023)
- Ad Hoc Group for Medical Research community letter: Urging Swift Passage of FY23 Spending Package (Nov 2022)
- Ad Hoc Group for Medical Research community letter: Fiscal Year 2023 Recommendation (May 2022)
- Ad Hoc Group for Medical Research community letter: Fiscal Year 2022 Recommendation (Feb. 2021)
- Ad Hoc Group for Medical Research community letter: to President-elect Biden (Dec. 2020)
- ASHG Letter to Senate HELP Committee & House E&C Committee: USICA Conference Letter (May 2022)
- Research!America community letter: FY 2023 Appropriations (September 2022)
- Research!America community letter: FY 2023 302(b) funding allocation (May 2022)
- Research!America community letter: COVID-19 Related Research Relief (Dec. 2020)
- Comments Re: FDA Regulatory Oversight of Laboratory Developed Tests